$245 Million is the total value of Foresite Capital Management V, LLC's 17 reported holdings in Q1 2022. The portfolio turnover from Q4 2021 to Q1 2022 was 6.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Pardes Biosciences Inc | $67,872,000 | -55.9% | 9,400,515 | 0.0% | 27.72% | -26.7% | ||
| Theseus Pharmaceuticals, Inc. | $37,043,000 | -9.1% | 3,212,732 | 0.0% | 15.13% | +51.1% | ||
| Sell | Somalogic, Inc. | $29,886,000 | -51.8% | 3,726,472 | -30.0% | 12.20% | -19.9% | |
| ACRS | Aclaris Therapeutics, Inc. | $21,692,000 | +18.6% | 1,258,243 | 0.0% | 8.86% | +97.1% | |
| HIMS | Buy | Hims & Hers Health, Inc. | $14,428,000 | +29.1% | 2,706,922 | +58.6% | 5.89% | +114.5% |
| ACET | Adicet Bio, Inc. | $13,580,000 | +14.2% | 680,000 | 0.0% | 5.55% | +89.8% | |
| QSI | Quantum-Si Incorporated | $10,961,000 | -40.5% | 2,342,061 | 0.0% | 4.48% | -1.2% | |
| CGEM | Sell | Cullinan Oncology, Inc. | $10,392,000 | -41.1% | 992,507 | -13.2% | 4.24% | -2.1% |
| KNTE | Kinnate Biopharma Inc. | $9,853,000 | -36.5% | 875,001 | 0.0% | 4.02% | +5.6% | |
| Sell | Adagio Therapeutics, Inc. | $6,529,000 | -48.5% | 1,431,826 | -17.9% | 2.67% | -14.4% | |
| CMPX | Compass Therapeutics, Inc. | $6,028,000 | -56.8% | 4,400,000 | 0.0% | 2.46% | -28.2% | |
| RACB | Research Alliance Corp. II | $4,880,000 | -0.1% | 500,000 | 0.0% | 1.99% | +66.1% | |
| GMTX | Gemini Therapeutics, Inc. | $3,385,000 | -52.2% | 2,435,125 | 0.0% | 1.38% | -20.6% | |
| Sell | Cue Health Inc. | $3,164,000 | -79.8% | 490,546 | -58.0% | 1.29% | -66.4% | |
| ENTA | New | Enanta Pharmaceuticals, Inc. | $3,007,000 | – | 42,250 | +100.0% | 1.23% | – |
| ME | 23andMe Holding Co. | $1,558,000 | -42.5% | 406,913 | 0.0% | 0.64% | -4.5% | |
| PHVS | Pharvaris N.V. | $619,000 | +26.1% | 34,142 | 0.0% | 0.25% | +109.1% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-05-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Kinnate Biopharma Inc. | 12 | Q3 2023 | 25.8% |
| Hims & Hers Health, Inc. | 11 | Q3 2023 | 37.5% |
| Aclaris Therapeutics, Inc. | 11 | Q3 2023 | 15.4% |
| Pharvaris N.V. | 11 | Q3 2023 | 5.5% |
| Quantum-Si Incorporated | 9 | Q2 2023 | 11.3% |
| TheseusPharmaceuticals, Inc. | 8 | Q3 2023 | 24.4% |
| Somalogic, Inc. | 8 | Q2 2023 | 20.5% |
| Compass Therapeutics, Inc. | 8 | Q3 2023 | 17.2% |
| Pardes Biosciences Inc | 7 | Q2 2023 | 37.8% |
| Gemini Therapeutics, Inc. | 7 | Q3 2022 | 9.7% |
View Foresite Capital Management V, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-04-05 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-13 |
| 4 | 2023-08-31 |
| 13F-HR | 2023-08-11 |
| 4 | 2023-07-19 |
| 13F-HR | 2023-05-12 |
| 4 | 2023-05-10 |
| 4 | 2023-04-06 |
| 4 | 2023-02-22 |
View Foresite Capital Management V, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.